http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105063055-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-173 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-115 |
| filingDate | 2015-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105063055-B |
| titleOfInvention | A kind of heteronuclear glycosides or the Tenascin-C aptamer GBI-10 of different nucleoside combinations 2 '-deoxyinosine modification and its preparation method and application |
| abstract | Tenascin-C aptamer GBI 10 modified the present invention relates to a kind of heteronuclear glycosides or the different deoxyinosine of nucleoside combinations 2 ' and its preparation method and application, belongs to biomedicine field.The present invention is replaced the nucleotide of the diverse location of Tenascin-C aptamer GBI 10 using heteronuclear glycosides or the different deoxyinosine of nucleoside combinations 2 ', change the local space conformation of aptamer, optimize its space structure, so as to obtain a kind of heteronuclear glycosides or the Tenascin-C aptamer GBI 10 of the different deoxyinosine of nucleoside combinations 2 ' modification.Experiment proves that the Tenascin-C aptamer GBI 10 after this method is modified and target protein have stronger affinity and more specific targets identification to act on, and has the bioactivity of higher.Therefore, it is hopeful the Tenascin-C aptamer GBI 10 of heteronuclear glycosides or the modification of the different deoxyinosine of nucleoside combinations 2 ' being prepared into efficiently, high selectivity, the antitumor drug of less toxic side effect, can also be applied in tumour early detection reagent. |
| priorityDate | 2015-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 98.